Arrowstreet Capital
EPRX

Arrowstreet Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Arrowstreet Capital’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-278,064
Closed -$2.09M – 2127
2025
Q4 		$2.09M Buy
+278,064
New +$1.71M ﹤0.01% 1392

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Arrowstreet Capital's EPRX Position: Q1 2026 in Review

Arrowstreet Capital sold out of Eupraxia Pharmaceuticals (EPRX) in Q1 2026, closing a stake of 278,064 shares — an estimated $2.09M sold.

Arrowstreet Capital first reported a position in EPRX in Q4 2025 and held it in 1 quarter. The position peaked at $2.09M in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Arrowstreet Capital reported no remaining Eupraxia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 278,064 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $2.09M.
  • Arrowstreet Capital first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Arrowstreet Capital's Eupraxia Pharmaceuticals position peaked at $2.09M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.